| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528798 | Current Opinion in Pharmacology | 2017 | 4 Pages |
Abstract
Evidence for the potential utility of GABAB antagonists has been assembled from a variety of sources, including clinical experience with the GABAB agonist baclofen, murine genetic GABAB knock-outs, rodent studies of GABAB receptor expression and function following treatment with antidepressant therapies, animal models of depression, and some functional and post mortem data from human subjects. Definitive testing of GABAB antagonists in depression, however, still awaits the development of potent, selective and brain-penetrant compounds for human testing.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Robert C Alexander,